Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer